Clabax OD (clarіthromycin) tablets with prolonged release 500 mg. №5


Manufacturer: India



Treatment of infections caused by clarithromycin-sensitive microorganisms:

infections of the upper respiratory tract, i.e. the nasopharynx (tonsillitis, pharyngitis), and infections of the paranasal sinuses;
infections of the lower respiratory tract (bronchitis, acute lobar pneumonia and primary atypical pneumonia)
skin and soft tissue infections (impetigo, folliculitis, erysipeloid, furunculosis, infected wounds)
acute and chronic odontogenic infections;
disseminated or localized mycobacterial infections caused by Mycobacterium avium or Mycobacterium intracellulare. Localized infections caused by Mycobacterium chelonae, Mycobacterium fortuitum, or Mycobacterium kansasi;
H. pylori eradication in patients with duodenal ulcer with inhibition of hydrochloric acid secretion (clarithromycin activity against H. pylori at neutral pH is higher than at acidic pH).